Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Mar. 06, 2026	Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan	Products
Mar. 04, 2026	Posted Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma - [Webcast]	Finances
Mar. 03, 2026	Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions	Corporate
Mar. 02, 2026	Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -)（PDF/3,386KB）	Finances
Mar. 02, 2026	Announcement of Filing of Shelf Registration Statement for Issuance of New Shares	Finances
Mar. 02, 2026	Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma -	Finances

May 13, 2026	FY2025 financial results announcement (scheduled to be disclosed at 1:00 p.m.), conference on financial results FY2025 for Analysts, Investors, and the Press